Western equine encephalitis virus glycoprotein (WEEV GP)

The Western equine encephalitis virus (WEEV) glycoprotein complex, primarily composed of the E1 and E2 heterodimers, serves as the essential machinery for viral attachment and entry into host cells. E2 mediates receptor binding, while E1 is a class II fusion protein that triggers membrane fusion within the endosome following endocytosis (UniProt: P13896). As the principal surface antigen, it is the primary target for neutralizing antibodies and the focus of vaccine strategies aimed at preventing Western equine encephalitis, a potentially fatal neuroinvasive disease (PubMed: 25122783). Therapeutic interventions under investigation include monoclonal antibodies that block the E2-receptor interaction or inhibit the E1 conformational change required for fusion (PubMed: 17507482). Despite its clinical significance as a biothreat agent and a zoonotic pathogen, no specific antivirals or licensed human vaccines currently exist, highlighting the glycoprotein's importance as a therapeutic target (NIH). Challenges in targeting this molecule include the high mutation rate of the RNA genome and the potential for antibody-dependent enhancement (ADE).

Other names

WEEV E1/E2 complexWEEV envelope proteinWEEV spike proteinWestern equine encephalitis virus E1 proteinWestern equine encephalitis virus E2 protein

Neutralization of viral infectivity by blocking receptor binding (E2) or inhibiting pH-dependent membrane fusion (E1) within the host endosome.